Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 3
1958 1
1965 3
1990 1
1991 1
1994 2
1995 2
1996 3
1997 3
1998 3
1999 8
2000 7
2001 13
2002 6
2003 2
2004 5
2005 11
2006 17
2007 16
2008 23
2009 18
2010 21
2011 27
2012 28
2013 42
2014 50
2015 58
2016 61
2017 73
2018 66
2019 79
2020 110
2021 81
2022 131
2023 15
Text availability
Article attribute
Article type
Publication date

Search Results

867 results
Results by year
Filters applied: . Clear all
Page 1
The gut metabolite indole-3 propionate promotes nerve regeneration and repair.
Serger E, Luengo-Gutierrez L, Chadwick JS, Kong G, Zhou L, Crawford G, Danzi MC, Myridakis A, Brandis A, Bello AT, Müller F, Sanchez-Vassopoulos A, De Virgiliis F, Liddell P, Dumas ME, Strid J, Mani S, Dodd D, Di Giovanni S. Serger E, et al. Among authors: kong g. Nature. 2022 Jul;607(7919):585-592. doi: 10.1038/s41586-022-04884-x. Epub 2022 Jun 22. Nature. 2022. PMID: 35732737
Reversible CD8 T cell-neuron cross-talk causes aging-dependent neuronal regenerative decline.
Zhou L, Kong G, Palmisano I, Cencioni MT, Danzi M, De Virgiliis F, Chadwick JS, Crawford G, Yu Z, De Winter F, Lemmon V, Bixby J, Puttagunta R, Verhaagen J, Pospori C, Lo Celso C, Strid J, Botto M, Di Giovanni S. Zhou L, et al. Among authors: kong g. Science. 2022 May 13;376(6594):eabd5926. doi: 10.1126/science.abd5926. Epub 2022 May 13. Science. 2022. PMID: 35549409
Reactive oxygen species regulate axonal regeneration through the release of exosomal NADPH oxidase 2 complexes into injured axons.
Hervera A, De Virgiliis F, Palmisano I, Zhou L, Tantardini E, Kong G, Hutson T, Danzi MC, Perry RB, Santos CXC, Kapustin AN, Fleck RA, Del Río JA, Carroll T, Lemmon V, Bixby JL, Shah AM, Fainzilber M, Di Giovanni S. Hervera A, et al. Among authors: kong g. Nat Cell Biol. 2018 Mar;20(3):307-319. doi: 10.1038/s41556-018-0039-x. Epub 2018 Feb 12. Nat Cell Biol. 2018. PMID: 29434374
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Among authors: kong g. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J. You X, et al. Among authors: kong g. Blood. 2022 Feb 17;139(7):1066-1079. doi: 10.1182/blood.2021012519. Blood. 2022. PMID: 34699595
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS. Violet J, et al. Among authors: kong g. J Nucl Med. 2019 Apr;60(4):517-523. doi: 10.2967/jnumed.118.219352. Epub 2018 Oct 5. J Nucl Med. 2019. PMID: 30291192 Free article. Clinical Trial.
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A, Mooi J, Tran B, Guo C, Kalff V, Murphy DG, Jackson P, Eu P, Scalzo M, Williams S, Hicks RJ, Hofman MS. Violet J, et al. Among authors: kong g. J Nucl Med. 2020 Jun;61(6):857-865. doi: 10.2967/jnumed.119.236414. Epub 2019 Nov 15. J Nucl Med. 2020. PMID: 31732676 Free PMC article. Clinical Trial.
867 results